化疗药物诱导的手足综合症

中国临床药理学与治疗学 ›› 2009, Vol. 14 ›› Issue (2): 210-213.

化疗药物诱导的手足综合症

张水华, 梅其炳, 潘学营, 马璟

上海医药工业研究院国家上海新药安全评价研究中心, 上海201203

收稿日期:2008-11-19 修回日期:2009-02-10 出版日期:2009-02-26 发布日期:2020-10-30
通讯作者: 马璟, 女, 研究员, 硕士研究生导师, 研究方向:药物毒理学。Tel:021-50800333-101 　E-mail:jma@ncdser.com
作者简介:张水华, 男, 在读博士研究生, 研究方向:药物毒理学。Tel:13818925931 　E-mail:zshjxau@163.com
基金资助:
上海市科委纳米专项(0652 nm016、0752 nm021)

Hand-foot syndrome induced by chemotherapy drugs

ZHANG Shui-hua, MEI Qi-bing, PAN Xue-ying, MA Jing

National Shanghai Center for New Drug Safety Evaluation and Research, Shanghai Institute of Pharmaceutical Industry, Shanghai 201203, China

Received:2008-11-19 Revised:2009-02-10 Online:2009-02-26 Published:2020-10-30

摘要/Abstract

摘要： 手足综合症(HFS)通常是由化疗药物诱导的一种皮肤毒性反应, 许多化疗药物在不同程度上表现出这一不良反应。本综述介绍了HFS 的临床表现、毒性分级、导致这一症状的常见化疗药物及其可能的病因、预防与治疗措施等。

关键词: 手足综合症, 化疗药物, 皮肤毒性

Abstract: Hand-foot syndrome is a cutaneous toxic reaction that is often induced by chemotherapy drugs, many chemotherapy drugs have been reported to cause the condition to the different degree.This review introduces clinical manifestation, toxic classification, frequent chemotherapy drugs, pathogenesis, preventive and treatment measures for HFS.

Key words: hand-foot syndrome, chemotherapy drugs, cutaneous toxicity

中图分类号:

R751

张水华, 梅其炳, 潘学营, 马璟. 化疗药物诱导的手足综合症[J]. 中国临床药理学与治疗学, 2009, 14(2): 210-213.

ZHANG Shui-hua, MEI Qi-bing, PAN Xue-ying, MA Jing. Hand-foot syndrome induced by chemotherapy drugs[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2009, 14(2): 210-213.

参考文献

[1] Nagore E, Insa A, Sanmartin O.Antineoplastic therapyinduced palmar plantar erythrodysesthesia ('hand-foot') syndrome.incidence, recognition and management[J]. Am J Clin Dermatol, 2000, 1(4):225-234.
[2] Zuehlke RK.Erythematous eruption of the palms and soles associated with mitotane therapy [J].Dermatologica, 1974, 148(2):90-92.
[3] Wilkes GM, Doyle D.Palmar-plantar erythrodysesthesia [J].J Oncol Pharm Practice, 2003, 9(4):137-150.
[4] Hellier I, Bessis D, Sotto A, et al.High-dose methotrexate-induced bullous variant of acral erythema[J].Arch Dermatol, 1996, 132(5):590-591.
[5] Blum JL, Jones SE, Buzdar AU, et al.Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer[J].J Clin Oncol, 1999, 17(2):485-493.
[6] Lorusso D, Stefano A Di, Carone V, et al.Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (hand-foot syndrome)[J].Ann Onc, 2007, 18(7):1159-1164.
[7] Tardi PG, Boman NL, Cullis PR.Liposomal Doxorubicin [J].J Drug Target, 1996, 4(3):129-140.
[8] Gordon KB, Tajuddin A, Guitart J, et al.Hand-foot syndrome associated with liposome-encapsulated doxorubicin therapy[J].Cancer, 1995, 75(8):2169-2173.
[9] Muggia FM, Hainsworth JD, Jeffers S, et al.Phase II study of liposomal doxorubicin in refractarory ovarian cancer:antitumor activity and toxicity modification by liposomal encapsulation[J].J Clin Oncol, 1997, 15(3):987-993.
[10] Uziely B, Jeffers S, Isacson R, et al.Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies[J].J Clin Oncol, 1995, 13 (7):1777-1785.
[11] Lyass O, Uziely B, Ben-Yosef R, et al.Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma[J].Cancer, 2000, 89(5):1037-1047.
[12] 陈新谦, 金有豫, 汤光.新编药物学[M].北京:人民卫生出版社, 2003:676.
[13] Douillard JY, Hoff PM, Skillings JR, et al.Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer[J].J Clin Oncol, 2002, 20(17):3605-3616.
[14] Milano G, Etienne-Grimaldi MC, Mari M, et al.Candidate mechanisms for capecitabine-related hand-foot syndrome[J].Br J Clin Pharmacol, 2008, 66(1):88-95.
[15] Toxicity of fluorouracil in patients with advanced colorectal cancer:effect of administration schedule and prognostic factors.Meta-Analysis Group In Cancer[J].J Clin Oncol, 1998, 16(11):3537-3541.
[16] Chiara S, Nobile MT, Barzacchi C.Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion[J].Eur J Cancer, 1997, 33(6):967-969.
[17] Kroll SS, Koller CA, Kaled S, et al.Chemotherapyinduced acral erythema:desquaminating lesions involving hands and feet[J].Ann Plast Surg, 1989, 23(3):263-265.
[18] Mangili G, Petrone M, Gentile C, et al.Prevention strategies in palmar-plantar erythrodysesthesia onset:the role of regional cooling[J].Gynecol Oncol, 2008, 108(2):332-335.
[19] Fabian CJ, Molina R, Slavik M, et al.Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continous 5-fluorouracil infusion [J].Invest New Drugs, 1990, 8(1):57-63.
[20] Vail DM, Chun R, Tham DH, et al.Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth)liposomes:a randomized double-blind clinical trial using a canine model [J].Clin Cancer Res, 1998, 4(6):1567-1571.
[21] Eng C, Mauer AM, Fleming GF, et al.Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cicplatin in patients with advanced solid tumors[J].Ann Oncol, 2001, 12(12):1743-1747.
[22] Drake RD, Lin WM, King M, et al.Oral dexamethasone attenuates Doxil(r)-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies [J].Gynecol Oncol, 2004, 94(2):320-324.
[23] Brown J, Burck K, Black D, et al.Treatment of cytarabine acral erythema with corticosteroids[J].J Am Acad Dermatol, 1991, 24(6Pt 1):1023-1025.
[24] Lopez A, Wallace L, Dorr R, et al.Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmarplantar erythrodysesthesia[J].Cancer Chemother Phamacol, 1999, 44(4):303-306.
[25] vonMoos R, Thuerlimann BJ, AaproM.Pegylated liposomal doxorubicin-associated hand-foot syndrome:recommendations of an international panel of experts[J].Eur J Cancer, 2008, 44(6):781-790.
[26] Solomon SD, McMurray JJ, Pfeffer MA, et al.Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention[J].N Engl J Med, 2005, 352(11):1071-1780.